TuHURA Biosciences (NASDAQ:HURA - Get Free Report)'s stock price fell 2.6% on Thursday . The company traded as low as $4.66 and last traded at $4.92. 320,091 shares changed hands during trading, an increase of 42% from the average session volume of 224,917 shares. The stock had previously closed at $5.05.
Analysts Set New Price Targets
A number of research analysts have issued reports on the stock. Rodman & Renshaw assumed coverage on shares of TuHURA Biosciences in a research note on Thursday, December 19th. They set a "buy" rating and a $11.00 target price for the company. Maxim Group initiated coverage on shares of TuHURA Biosciences in a research note on Tuesday, November 5th. They issued a "buy" rating and a $15.00 price target for the company. Finally, RODMAN&RENSHAW raised shares of TuHURA Biosciences to a "strong-buy" rating in a research note on Thursday, December 19th.
Read Our Latest Report on TuHURA Biosciences
TuHURA Biosciences Stock Performance
The business's 50 day moving average is $4.75.
Institutional Trading of TuHURA Biosciences
An institutional investor recently bought a new position in TuHURA Biosciences stock. Apollon Wealth Management LLC bought a new stake in shares of TuHURA Biosciences (NASDAQ:HURA - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 61,772 shares of the company's stock, valued at approximately $253,000. Apollon Wealth Management LLC owned about 0.15% of TuHURA Biosciences at the end of the most recent reporting period. Institutional investors own 0.62% of the company's stock.
TuHURA Biosciences Company Profile
(
Get Free Report)
TuHURA Biosciences, Inc NASDAQ: HURA is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.
Recommended Stories
Before you consider TuHURA Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TuHURA Biosciences wasn't on the list.
While TuHURA Biosciences currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
